C2I Alumin, Frequency Therapeutics, Announces Positive Phase 1/2 Data for Drug Candidate for Hearing

We would like to extend our congratulations to our alumni, Frequency Therapeutics, upon their announcement of positive results from a Phase 1/2 safety trial to evaluate FX-322. FX-322 is an investigational drug candidate designed to facilitate hearing restoration.

If successful, Frequency Therapeutic's lead development program would represent the first time that hearing could be restored in humans with a therapeutic. Their work is "defining a new mode of regenerative medicine: activating progenitor cells within your body to repair damaged tissue."

To read the full article:

https://www.businesswire.com/news/home/20190409005363/en/Frequency-Therapeutics-Announces-Positive-Phase-12-Data

Featured Posts
Recent Posts
Archive
Search By Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • LinkedIn Social Icon

© 2019 by CreaGen Inc. 

299 Washington St

Woburn, MA 01801 

Tel: 781.938.1122

Fax: 781.938.1123

 

info@creagenbio.com

  • Grey LinkedIn Icon
  • Grey Twitter Icon
  • Grey YouTube Icon
  • Grey Facebook Icon

Business Accelerator | CreaGen C2I | Life Science | Lease Lab Space | Biotech